

**February 13, 2020**

TAKE/BSE/2019-20  
The Manager  
Dept. of Corporate Services-Listing  
Bombay Stock Exchange Limited,  
P. J. Towers, Dalal Street,  
Mumbai – 400001  
Scrip Code: 532890

TAKE/NSE/2019-20  
The Manager-Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza,  
Bandra - Kurla Complex, Bandra (East),  
Mumbai – 400051  
Symbol: TAKE

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting held on Thursday, February 13, 2020**

We wish to inform you that the Board of Directors of the Company, in its meeting held on Thursday, February 13, 2020, approved/took note of the following:

1. Unaudited Financial Results of the Company (Standalone) and together with its subsidiaries (Consolidated) for the third quarter ended December 31, 2019 as recommended by the Audit Committee. Copy of the same in the prescribed format in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, along with the Limited Review Report by the Statutory Auditor, is enclosed herewith.
  
2. Decided not to declare any dividend for the quarter ended December 31, 2019.

The meeting of Board of Directors of the Company commenced at 11:00 AM and concluded at 2.00 PM.

Please take note of the same.

Thanking you,

Yours sincerely,  
**For TAKE Solutions Limited**

  
Avaneesh Singh  
Company Secretary

Encl: A/a



## Limited Review Report

The Board of Directors  
TAKE Solutions Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of TAKE Solutions Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended December 31, 2019 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the consolidation of results pertaining to the entities listed in Annexure.
5. Based on our review conducted and procedures performed as stated in paragraph 3 as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the

---

**Pune Office:** GDA House, Plot No.85, Right Bhusari Colony, Paud Road, Kothrud, Pune – 411 038, Phone – 020 – 25280081,  
Fax No. 25280275, Email – [audit@gdaca.com](mailto:audit@gdaca.com)

**Mumbai Office:** Windsor, 6<sup>th</sup> Floor, OfficeNo-604, C.S.T. Road, Kalina, Santacruz (East), Mumbai-400 098



**G. D. Apte & Co.  
Chartered Accountants**

---

SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G. D. Apte & Co.  
Chartered Accountants  
Firm Registration Number: 100515W



Umesh S. Abhyankar  
Partner  
Membership Number: 113053  
UDIN : 20113053AAAAAJ2046  
Chennai, February 13, 2020



**Annexure**

**Annexure referred to in Paragraph 4 of our Limited Review Report on the Consolidated Financial Results of TAKE Solutions Limited for the Quarter and Nine months ended December 31, 2019**

Sr. No.	Particulars
<b>A</b>	<b>Subsidiaries</b>
1	APA Engineering Private Limited
2	Ecron Acunova Limited
3	TAKE Solutions Global Holding Pte Ltd.
4	TAKE Solutions Limited ESOP Trust
5	Navitas LLP
<b>B</b>	<b>Step Down Subsidiaries</b>
1	APA Engineering Pte Ltd, Singapore
2	APA Engineering Inc., USA
3	TAKE Solutions Information Systems Pte Ltd, Singapore
4	TAKE Enterprise Services Inc., USA
5	TAKE Innovations Inc , USA
6	Navitas Life Sciences Holdings Limited, UK
7	Million Star Technologies Limited, Mauritius
8	Intelent Inc, USA
9	Navitas Life Sciences Limited, UK
10	Navitas Inc., USA
11	Navitas Life Sciences S.A.S. Colombia
12	Acunova Life Science Inc., USA
13	Navitas Lifesciences Company Limited, Thailand



G. D. Apte & Co.  
Chartered Accountants

---

14	Acunova Life Sciences Limited, UK
15	Navitas Life Sciences, GmbH, Germany
16	Ecron Acunova Sdn. Bhd., Malaysia
17	Ecron Acunova Sp. Z. O. O., Poland
18	Ecron LLC, Ukraine
19	Ecron Acunova LLC, Russia
20	Navitas Life Sciences A/S, Denmark
21	Navitas Life Sciences Pte Ltd, Singapore



---

**Pune Office:** GDA House, Plot No.85, Right Bhusari Colony, Paud Road, Kothrud, Pune – 411 038, Phone – 020 – 25280081,  
Fax No. 25280275, Email – [audit@gdaca.com](mailto:audit@gdaca.com)

**Mumbai Office:** Windsor, 6<sup>th</sup> Floor, OfficeNo-604, C.S.T. Road, Kalina, Santacruz (East), Mumbai-400 098



**TAKE SOLUTIONS LTD**  
CIN: L63090TN2000PLC046338  
Regd. Office : 27, Tank Bund Road, Nungambakkam, Chennai 600 034  
[www.takesolutions.com](http://www.takesolutions.com)

**Statement of Unaudited Consolidated Financial Results for the quarter and nine months ended December 31, 2019**  
(₹ In Lakhs except per share data)

Sl. No.	Particulars	Quarter Ended			Nine months Ended		Year Ended
		Dec 31, 2019	Sep 30, 2019	Dec 31, 2018	Dec 31, 2019	Dec 31, 2018	Mar 31, 2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	65,110.93	60,838.13	52,164.02	184,223.36	150,506.05	203,899.85
2	Other Income	343.87	650.48	269.38	1,076.16	2,433.24	1,074.91
3	<b>Total Revenue</b>	<b>65,454.80</b>	<b>61,488.61</b>	<b>52,433.40</b>	<b>185,299.52</b>	<b>152,939.29</b>	<b>204,974.76</b>
4	<b>Expenses</b>						
	Cost of revenue	17,749.17	17,315.86	14,456.50	51,405.85	42,407.66	57,399.66
	Employee benefit expenses	19,835.45	17,500.89	15,623.74	53,541.52	43,591.04	59,162.26
	Finance cost	1,076.27	999.96	548.16	3,100.77	1,627.30	2,501.07
	Depreciation and amortisation	4,107.30	4,049.92	4,152.19	12,658.23	11,379.52	15,350.96
	Other expenses	16,693.39	15,422.21	13,261.11	46,888.43	35,821.24	48,991.88
	<b>Total Expenses</b>	<b>59,461.58</b>	<b>55,288.84</b>	<b>48,041.70</b>	<b>167,594.80</b>	<b>134,826.76</b>	<b>183,405.83</b>
5	<b>Profit/(Loss) before tax (3-4)</b>	<b>5,993.22</b>	<b>6,199.77</b>	<b>4,391.70</b>	<b>17,704.72</b>	<b>18,112.53</b>	<b>21,568.93</b>
6	<b>Tax expense</b>						
	Current tax	1,048.53	1,358.23	575.79	3,364.74	2,537.45	3,199.40
	Shortfall / (excess) provision of earlier years	(150.71)	(21.28)	0.20	(171.99)	19.23	27.31
	Deferred tax	(19.05)	(235.24)	178.89	(309.00)	422.83	502.99
7	<b>Profit/(Loss) for the period (5-6)</b>	<b>5,114.45</b>	<b>5,098.06</b>	<b>3,636.82</b>	<b>14,820.97</b>	<b>15,133.02</b>	<b>17,839.23</b>
	<b>Attributable to:</b>						
	Shareholders of the company	5,043.84	5,002.47	3,576.17	14,557.01	14,941.72	17,729.64
	Non-controlling interest	70.61	95.59	60.65	263.96	191.30	109.59
8	<b>Other Comprehensive Income</b>						
	a) i) Items that will not be reclassified to profit or (loss)	(26.56)	(63.30)	(29.10)	(128.19)	6.41	(42.31)
	ii) Income tax provision / (reversal) relating to the items that will not be reclassified to profit or (loss)	(8.47)	(21.25)	(9.68)	(42.25)	(4.47)	(13.24)
	b) i) Items that will be reclassified to profit or (loss)	3,274.14	(1,958.19)	(3,916.55)	4,127.12	4,763.80	3,213.36
	ii) Income tax provision / (reversal) relating to the items that will be reclassified to profit or (loss)	(10.89)	8.24	28.71	(10.75)	(15.45)	17.34
	<b>Total Other Comprehensive Income</b>	<b>3,266.94</b>	<b>(2,008.48)</b>	<b>(3,964.68)</b>	<b>4,051.93</b>	<b>4,790.13</b>	<b>3,166.95</b>
	<b>Attributable to:</b>						
	Shareholders of the company	3,267.01	(2,008.78)	(3,964.63)	4,051.93	4,789.90	3,167.05
	Non-controlling interest	(0.07)	0.30	(0.05)	-	0.23	(0.10)
9	<b>Total Comprehensive Income</b>	<b>8,381.39</b>	<b>3,089.58</b>	<b>(327.86)</b>	<b>18,872.90</b>	<b>19,923.15</b>	<b>21,006.18</b>
	<b>Attributable to:</b>						
	Shareholders of the company	8,310.85	2,993.69	(388.46)	18,608.94	19,731.62	20,896.69
	Non-controlling interest	70.54	95.89	60.60	263.96	191.53	109.49
10	<b>Paid-up equity share capital (Face value ₹ 1/- each)</b>	<b>1,462.20</b>	<b>1,462.20</b>	<b>1,461.29</b>	<b>1,462.20</b>	<b>1,461.29</b>	<b>1,461.36</b>
11	<b>Earnings per share (of ₹ 1/- each not annualised)</b>						
	(a) Basic	3.45	3.42	2.45	9.96	10.23	12.13
	(b) Diluted	3.45	3.42	2.44	9.95	10.20	12.09

**Segment Wise Revenue and Results**  
**Primary Segment Information**

Particulars	(₹ In Lakhs)					
	Quarter Ended			Nine months Ended		Year Ended
	Dec 31, 2019	Sep 30, 2019	Dec 31, 2018	Dec 31, 2019	Dec 31, 2018	Mar 31, 2019
<b>1. Segment Revenue</b>						
(i) Life Sciences	61,531.12	57,200.55	48,259.19	173,596.73	138,051.26	188,048.57
(ii) Supply Chain Management	3,579.81	3,637.58	3,904.83	10,626.63	12,454.79	15,851.28
<b>Revenue from Operations</b>	<b>65,110.93</b>	<b>60,838.13</b>	<b>52,164.02</b>	<b>184,223.36</b>	<b>150,506.05</b>	<b>203,899.85</b>
<b>2. Segment Results</b>						
(i) Life Sciences	7,636.73	7,737.58	6,539.76	22,257.72	22,931.19	28,457.72
(ii) Supply Chain Management	347.51	341.07	212.01	1,051.86	462.89	456.48
<b>Total</b>	<b>7,984.24</b>	<b>8,078.65</b>	<b>6,751.77</b>	<b>23,309.58</b>	<b>23,394.08</b>	<b>28,914.20</b>
Less: (i) Finance cost	1,076.27	999.96	548.16	3,100.77	1,627.30	2,501.07
(ii) Other Un-allocable Expenditure net off Un-allocable Income	914.75	878.92	1,811.91	2,504.09	3,654.25	4,844.20
<b>Profit Before Tax</b>	<b>5,993.22</b>	<b>6,199.77</b>	<b>4,391.70</b>	<b>17,704.72</b>	<b>18,112.53</b>	<b>21,568.93</b>

Segregation of assets, liabilities, depreciation and other non-cash expenses into various primary segments has not been carried out as the assets are used interchangeably between segments. Accordingly, no disclosure relating to segmental assets and liabilities has been made.



**Note:**


- 1 The Consolidated Financial Results for the quarter and nine months ended December 31, 2019 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the company in their respective meetings held on February 13, 2020. The statutory auditors of the company have carried out Limited Review of the results for the quarter and nine months ended December 31, 2019.
- 2 Effective April 1, 2019, the Group adopted Ind AS 116 'Leases' and applied the same to the lease arrangements entered during the period from April 1, 2019 to December 31, 2019 and also for lease arrangements existing on April 1, 2019 using the modified retrospective approach recognizing right -of -use asset and corresponding lease liability. Accordingly , comparatives for the year ended March 31, 2019 and other periods disclosed have not been retrospectively adjusted. The effect of the adoption is not significant to the profit for the period.
- 3 The Consolidated and Standalone financial results for the quarter and nine months ended December 31, 2019 are available on the Company's website ([www.takesolutions.com](http://www.takesolutions.com)) and the website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com))
- 4 During the quarter ended December 31, 2019, employees have not exercised any share options under Employee Stock Option Scheme of the Group.
- 5 The financial results of TAKE Solutions Limited (Standalone information)

(₹ In Lakhs)

Particulars	Quarter Ended			Nine months Ended		Year Ended
	Dec 31, 2019	Sep 30, 2019	Dec 31, 2018	Dec 31, 2019	Dec 31, 2018	Mar 31, 2019
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income	1,205.70	1,201.78	3,014.98	3,046.23	9,145.47	5,630.74
Net profit/(loss) before tax	589.56	545.76	551.02	1,283.35	5,840.88	1,950.83
Net profit/(loss) for the period	659.33	608.72	538.45	1,426.24	5,492.97	1,739.47
Total comprehensive income	658.32	608.08	537.12	1,423.82	5,493.53	1,736.39

- 8 Previous period figures have been regrouped /reclassified, wherever necessary to conform to current period's classification.

For and on behalf of the Board of Directors



Srinivasan R.R.

Vice Chairman &amp; Managing Director



Place : Chennai  
Date : February 13, 2020



## Limited Review Report

The Board of Directors  
TAKE Solutions Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results (the statement) of TAKE Solutions Limited for the quarter and nine months ended December 31, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. The statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For G. D. Apte & Co.  
Chartered Accountants  
Firm Registration Number: 100515W



Umesh S. Abhyankar  
Partner  
Membership Number: 113053  
UDIN : 20113053AAAAI5592  
Chennai, February 13, 2020





## TAKE SOLUTIONS LTD

CIN: L63090TN2000PLC046338

Regd. Office : 27, Tank Bund Road, Nungambakkam, Chennai 600 034  
www.takesolutions.com

## Statement of Unaudited Standalone Financial Results for the quarter and nine months ended December 31, 2019

(₹ In Lakhs except per share data)

Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		Dec 31, 2019 (Unaudited)	Sep 30, 2019 (Unaudited)	Dec 31, 2018 (Unaudited)	Dec 31, 2019 (Unaudited)	Dec 31, 2018 (Unaudited)	Mar 31, 2019 (Audited)
1	Revenue from operations	43.79	91.28	1,487.55	183.53	1,552.40	2,195.86
2	Other Income	1,161.91	1,110.50	1,527.43	2,862.70	7,593.07	3,434.88
3	<b>Total Income</b>	<b>1,205.70</b>	<b>1,201.78</b>	<b>3,014.98</b>	<b>3,046.23</b>	<b>9,145.47</b>	<b>5,630.74</b>
4	<b>Expenses</b>						
	Cost of revenue	43.72	52.62	1,299.17	118.14	1,357.24	1,815.66
	Employee benefit expenses	131.34	166.37	165.21	483.71	456.29	682.19
	Finance cost	10.33	11.02	-	32.65	-	-
	Depreciation and amortisation	44.35	45.02	19.94	134.89	60.22	80.18
	Other expenses	386.40	380.99	979.64	993.49	1,430.84	1,101.88
	<b>Total Expenses</b>	<b>616.14</b>	<b>656.02</b>	<b>2,463.96</b>	<b>1,762.88</b>	<b>3,304.59</b>	<b>3,679.91</b>
5	<b>Profit/(Loss) before tax (3-4)</b>	<b>589.56</b>	<b>545.76</b>	<b>551.02</b>	<b>1,283.35</b>	<b>5,840.88</b>	<b>1,950.83</b>
6	<b>Tax expense</b>						
	Current tax	(3.67)	7.10	10.17	26.11	382.12	230.19
	Shortfall / (excess) provision of earlier years	(86.63)	-	-	(86.63)	-	-
	Deferred tax	20.53	(70.06)	2.40	(82.37)	(34.21)	(18.83)
7	<b>Profit/(Loss) for the period (5-6)</b>	<b>659.33</b>	<b>608.72</b>	<b>538.45</b>	<b>1,426.24</b>	<b>5,492.97</b>	<b>1,739.47</b>
8	<b>Other Comprehensive Income</b>						
a) i)	Items that will not be reclassified to profit or (loss)	(1.35)	(0.90)	(1.88)	(3.33)	0.73	(4.27)
	ii) Income tax provision / (reversal) relating to the items that will not be reclassified to profit or (loss)	(0.34)	(0.26)	(0.55)	(0.91)	0.17	(1.19)
b) i)	Items that will be reclassified to profit or (loss)	-	-	-	-	-	-
	ii) Income tax provision/(reversal) relating to the items that will be reclassified to profit or (loss)	-	-	-	-	-	-
	<b>Total Other Comprehensive Income</b>	<b>(1.01)</b>	<b>(0.64)</b>	<b>(1.33)</b>	<b>(2.42)</b>	<b>0.56</b>	<b>(3.08)</b>
9	<b>Total Comprehensive Income</b>	<b>658.32</b>	<b>608.08</b>	<b>537.12</b>	<b>1,423.82</b>	<b>5,493.53</b>	<b>1,736.39</b>
10	<b>Paid-up equity share capital (Face value ₹ 1/- each)</b>	<b>1,479.34</b>	<b>1,479.34</b>	<b>1,479.34</b>	<b>1,479.34</b>	<b>1,479.34</b>	<b>1,479.34</b>
11	<b>Earnings per share (of ₹ 1/- each) (not annualised)</b>						
	(a) Basic (in ₹)	0.45	0.41	0.36	0.97	3.71	1.18
	(b) Diluted (in ₹)	0.45	0.41	0.36	0.97	3.69	1.17

## Notes:

- The Standalone Financial Results for the quarter and nine months ended December 31, 2019 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the company in their respective meetings held on February 13, 2020. The statutory auditors of the company have carried out Limited Review of the results for the quarter and nine months ended December 31, 2019.
- Effective April 1, 2019, the Company adopted Ind AS 116 'Leases' and applied the same to the lease arrangements entered during the period from April 1, 2019 to December 31, 2019 and also for lease arrangements existing on April 1, 2019 using the modified retrospective approach recognizing right-of-use asset and corresponding lease liability. Accordingly , comparatives for the year ended March 31, 2019 and other periods disclosed have not been retrospectively adjusted. The effect of the adoption is not significant to the profit for the period.
- The company on a standalone basis operates in the business segment of promotion of services related to Life Sciences and hence there is only one business segment. The company on a standalone basis is primarily operating in India, which is considered as single geographical segment. Accordingly, segment information has not been separately disclosed.
- During the quarter ended December 31, 2019, employees have not exercised any share options under Employee Stock Option Scheme of the Company.
- Previous period figures have been regrouped /reclassified, wherever necessary to conform to current period's classification.

For and on behalf of the Board of Directors

Srinivasan H.R.  
Vice Chairman & Managing DirectorPlace : Chennai  
Date : February 13, 2020